Literature DB >> 9183605

Dobutamine stress echocardiography.

W Krahwinkel1, T Ketteler, J Gödke, J Wolfertz, L J Ulbricht, I Krakau, H Gülker.   

Abstract

Dobutamine is a synthetic catecholamine with predominant beta-stimulation. Its half-life is approximately 2 min. The positive chronotropic and inotropic effects of dobutamine induce myocardial ischaemia if significant coronary artery obstruction is present. Regional ischaemia produces regional wall motion abnormalities which can be detected by echocardiography. Most dobutamine stress protocols start at an infusion rate of 5 micrograms.kg-1.min-1 and increase to a peak dose of 40 or 50 micrograms.kg-1.min-1; to further increase heart rate, a bolus injection of 0.25-1.0 mg atropine is added. Test endpoints are the detection of new wall motion abnormalities, the occurrence of severe complications or achievement of the target heart rate. Viable myocardial regions have a positive inotropic reserve, which can be stimulated by dobutamine and detected by echocardiography. Indications for the use of dobutamine stress echocardiography are to prove stress-inducible myocardial ischaemia and to detect myocardial viability. The test should only be performed for the detection of stress-induced myocardial ischaemia if patients are unable to undergo exercise echocardiography, or if patients fail to reach their required test level in exercise echocardiography.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9183605     DOI: 10.1093/eurheartj/18.suppl_d.9

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

Review 1.  Challenging cardiac function post-spinal cord injury with dobutamine.

Authors:  Kathryn M DeVeau; Emily K Martin; Nicholas T King; Alice Shum-Siu; Bradley B Keller; Christopher R West; David S K Magnuson
Journal:  Auton Neurosci       Date:  2016-12-23       Impact factor: 3.145

Review 2.  [Methods for coronary functional assessment].

Authors:  M Elsner
Journal:  Herz       Date:  1998-03       Impact factor: 1.443

3.  Micro-CT imaging assessment of dobutamine-induced cardiac stress in rats.

Authors:  Cristian T Badea; Laurence W Hedlund; James Cook; Brian R Berridge; G Allan Johnson
Journal:  J Pharmacol Toxicol Methods       Date:  2010-04-23       Impact factor: 1.950

4.  Dobutamine stress echocardiography resulting in acute gastric dilatation and pneumoporta.

Authors:  Jml Williamson; D Mahon
Journal:  Ann R Coll Surg Engl       Date:  2016-07-07       Impact factor: 1.891

5.  Dobutamine stress echocardiography in healthy adult male rats.

Authors:  Eric Plante; Dominic Lachance; Marie-Claude Drolet; Elise Roussel; Jacques Couet; Marie Arsenault
Journal:  Cardiovasc Ultrasound       Date:  2005-10-26       Impact factor: 2.062

6.  Graded Maximal Exercise Testing to Assess Mouse Cardio-Metabolic Phenotypes.

Authors:  Jennifer M Petrosino; Valerie J Heiss; Santosh K Maurya; Anuradha Kalyanasundaram; Muthu Periasamy; Richard A LaFountain; Jacob M Wilson; Orlando P Simonetti; Ouliana Ziouzenkova
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

7.  Cardiac stress testing and coronary artery disease in liver transplantation candidates: Meta-analysis.

Authors:  Jonathan Soldera; Fábio Camazzola; Santiago Rodríguez; Ajacio Brandão
Journal:  World J Hepatol       Date:  2018-11-27

8.  Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults.

Authors:  Günther Krumpl; Ivan Ulč; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  BMC Pharmacol Toxicol       Date:  2020-11-25       Impact factor: 2.483

Review 9.  Taxonomy of segmental myocardial systolic dysfunction.

Authors:  Adam K McDiarmid; Pierpaolo Pellicori; John G Cleland; Sven Plein
Journal:  Eur Heart J       Date:  2017-04-01       Impact factor: 29.983

10.  The assessment of coronary artery disease in patients with end-stage renal disease.

Authors:  Federica E Poli; Gaurav S Gulsin; Gerry P McCann; James O Burton; Matthew P Graham-Brown
Journal:  Clin Kidney J       Date:  2019-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.